Parenteral Nutrition Market Size, Share, Industry, Forecast and outlook 2026-2033

Parenteral Nutrition Market Size

The global parenteral nutrition market size was estimated at approximately USD 8.02 billion in 2025 and is projected to reach around USD 12.72 billion by 2033, growing at a CAGR of 5.8% during the forecast period 2026–2033.

Parenteral nutrition is a method of getting nutrition into the body through the veins, which include amino acids, carbohydrates, fat, minerals and electrolytes, vitamins, trace elements, and others. for patients who cannot eat or absorb enough food through tube feeding formula or by mouth to maintain proper nutrition status. It is delivered either peripherally or centrally, through the superior vena cava, this helps in crossing the first-pass effect.

Parenteral Nutrition Market Scope

For More Inisghts about the Market Request Free Sample

Parenteral Nutrition Market Dynamics

The increasing occurrence of chronic conditions, such as cancer, is influencing the global parenteral nutrition market positively. The benefit of parenteral nutrition in chronic diseases helps in the provision of vital nutrients that help in maintaining the hydration level, strength, and energy to the patients. According to the International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases worldwide, by 2040, it is expected to reach 27.5 million new cancer cases due to the growth and aging of the population. Thus, the increase in cancer cases is expected to drive the global parenteral nutrition market.

The rise in pediatric disorders will create mineral and vitamin deficiencies amongst children that will fuel the demand for parenteral nutrition products, thereby increasing the market growth. Additionally, extensive research and development activities by key players to develop new parenteral nutrition products and rising approvals to new parenteral nutrition components drive the market. In October 2018, Baxter in collaboration with the American Society for Parenteral and Enteral Nutrition (ASPEN) launched the ‘smartPN’ tool to reduce clinical malnutrition.

Parenteral Nutrition Market Segmentation Analysis

Based on type- the global Parenteral Nutrition market is broadly segmented as amino acid, fats, minerals & vitamins, parenteral lipid emulsions, trace elements, and others. Among all, amino acids accounted for a major market share in 2024 and are projected to grow at a high CAGR over the forecast period (2025-2031). It is due to increasing cases of renal insufficiency, hepatic insufficiency, and protein-catabolic critical illness that will globally boost the demand for amino acid-based parenteral nutrition products.

Additionally, deficiency of energy and dietary proteins are customary in critically-ill hospitalized patients that ultimately lead to protein-energy malnutrition. Over the forecast period, parenteral lipid emulsion is expected to grow at a significant rate. Lipid emulsions are prescribed for pediatric patients as they are a non-carbohydrate source of energy. These lipid emulsions are a rich source of essential fatty acids. Also useful in maintaining overall nitrogen balance in parenteral nutrition solutions.

Parenteral Nutrition Market Geographical Share

The global Parenteral Nutrition market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America region accounted for major market share in 2025 and is projected to grow at a significant rate during the forecast period (2025-2031).

The region will witness positive growth owing to a rise in awareness about parenteral nutrition, increasing incidence of chronic diseases coupled with rising healthcare expenses, the existence of advanced healthcare facilities, as well as favorable reimbursement policies. Asia Pacific is projected to grow at a significant pace over the forecast period, owing to the rapidly increasing population prone to malnutrition, rise in awareness among people, and modernizing of healthcare infrastructure in developing nations such as China and India in this region.

Parenteral Nutrition Manufacturers and Competition Landscape

Significant players of the global parenteral nutrition market are Sichuan Kelun Pharmaceutical Co., Ltd., Allergan plc (Actavis plc), Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., Claris Lifesciences Limited, B. Braun Melsungen AG, Pfizer, Inc., and others. The product launches, collaboration, and product agreements, and other key developments are the dominating strategies adopted by the market players to enhance their product portfolio in the parenteral nutrition market. For instance, in October 2018, Fresenius Kabi Announced U.S. Availability of Omegaven® (fish oil triglycerides) Injectable Emulsion.

Parenteral Nutrition Market Recent Developments

• June 2026 – Fresenius Kabi launches Pedismof® pediatric parenteral nutrition range in Europe
  Fresenius Kabi launched the Pedismof® range, a new ready-to-use three-chamber bag solution for pediatric parenteral nutrition. The age-specific formulations are designed for preterm and term neonates, infants, children, and adolescents, strengthening the company’s pediatric clinical nutrition portfolio.
• June 2026 – Fresenius strengthens medical nutrition innovation capabilities
  Fresenius opened a new Innovation Center for Medical Nutrition in Bad Homburg, Germany, to accelerate research, product development, and innovation in clinical nutrition. The facility is expected to support development of advanced medical nutrition solutions, including parenteral nutrition technologies.
• May 2026 – Fresenius Kabi expands parenteral nutrition market presence
  Fresenius Kabi reported continued market-share gains in U.S. parenteral nutrition and maintained strong momentum in its Nutrition business. The company is also accelerating its innovation pipeline and geographic expansion to strengthen its position in clinical nutrition.
• April 2026 – Orbicular, Gland Pharma and Apotex secure U.S. FDA approval for generic INFUVITE ADULT
  Orbicular Pharmaceutical Technologies, Gland Pharma, and Apotex received U.S. FDA approval for a generic INFUVITE ADULT injectable used in parenteral nutrition. The product received Competitive Generic Therapy designation and six-month market exclusivity, supporting greater availability of injectable multivitamins for PN applications.
• 2026 – Fresenius Kabi advances personalized parenteral nutrition R&D
  Fresenius Kabi is strengthening its global R&D capabilities for clinical nutrition, with its innovation activities including advanced technologies for personalized parenteral nutrition. Its nutrition R&D network is focused on developing solutions across parenteral nutrition, specialized medical nutrition, and renal nutrition.
• 2026 – B. Braun expands smart and patient-specific parenteral nutrition solutions
  B. Braun continues developing solutions aimed at simplifying PN preparation and improving patient safety, including compatibility and stability guidance, automated compounding technologies, and patient-specific formulations. These capabilities support growing demand for individualized nutrition therapy in hospitals and home-care settings.
• August 2026 – ASPEN highlights safety and prescribing gaps in parenteral nutrition
  The American Society for Parenteral and Enteral Nutrition (ASPEN) highlighted continued progress in PN safety while identifying persistent prescribing gaps. Its 2026 resources also address PN use in adults with obesity and findings from U.S. PN practice-gap analysis, emphasizing the need for evidence-based and standardized nutrition support.
• 2026 – Baxter strengthens ready-to-use and customized PN capabilities
  Baxter continues to support the PN market through ready-to-use premixed formulations as well as pharmacy workflow, labeling, and compounding technologies for patients requiring individualized nutritional therapy. Its OLICLINOMEL portfolio provides multiple triple-chamber formulations designed around different protein and energy requirements.